Report of Foreign Issuer (6-k)
November 27 2017 - 7:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2017
001-36203
(Commission File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact name of Registrant as specified in
its charter)
10 Bareket Street
KiryatMatalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
____
The
first sentence of the first paragraph and “Forward Looking Statements” of the press release attached to this Form
6-K are hereby incorporated by reference into the registrant's Registration Statements on Form F-3 (File Nos. 333-195124, 333-199033,
333-204795, 333-209037 and 333-220644), to be a part thereof from the date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.
On November 27, 2017, Can-Fite
BioPharma Ltd. (the “Company”) issued a press release announcing that the first patient of the Company’s
Phase II trial of its drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH) was enrolled. A copy of this press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Can-Fite BioPharma Ltd.
|
|
|
|
Date: November 27, 2017
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
4
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024